HC Wainwright Reiterates Buy Rating for MetaVia (NASDAQ:MTVA)

MetaVia (NASDAQ:MTVA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $20.00 price objective on the stock.

A number of other equities analysts also recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. Wall Street Zen upgraded MetaVia from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, MetaVia presently has an average rating of “Hold” and a consensus price target of $26.50.

MetaVia Stock Performance

NASDAQ:MTVA remained flat at $1.11 during trading hours on Monday. The company’s stock had a trading volume of 13,404 shares, compared to its average volume of 215,152. MetaVia has a 52-week low of $0.97 and a 52-week high of $19.03. The stock has a market capitalization of $5.73 million, a PE ratio of -0.13 and a beta of 0.59. The firm’s fifty day simple moving average is $1.39 and its 200-day simple moving average is $4.51.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). As a group, sell-side analysts predict that MetaVia will post -2.72 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC increased its position in shares of MetaVia Inc. (NASDAQ:MTVA) by 44.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 60,386 shares of the company’s stock after acquiring an additional 18,506 shares during the period. SG Americas Securities LLC owned approximately 0.25% of MetaVia worth $57,000 at the end of the most recent quarter. 1.37% of the stock is owned by institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.